Two key mechanisms may explain this divergence from Semaglutide: (i) SURPASS enrolled participants with less severe baseline diabetic retinopathy compared to SUSTAIN
The bioavailability difference, approximately 3% to 15% for sublingual drops versus near-100% for injections, means less active compound reaches your bloodstream
Tracking progress beyond the scale If you take one thing from this entire article, let it be this: the scale is the least reliable measure of progress during tirzepatide treatment
Clinically, this moment is not the end of progress its the point where strategy matters most, which is why many patients begin exploring structured programs through providers like California Trim Clinic
When to contact your provider Some symptoms require medical attention regardless of where you are in the dosing protocol
What This Article Does Not Claim To be explicit about the limits of this review: This article does not claim that compounded GLP-1 medications are FDA-approved
